On Tuesday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) opened lower -4.63% from the last session, before settling in for the closing price of $14.9. Price fluctuations for PHAT have ranged from $2.21 to $16.26 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 12.50%. Company’s average yearly earnings per share was noted 40.26% at the time writing. With a float of $41.28 million, this company’s outstanding shares have now reached $71.04 million.
The extent of productivity of a business whose workforce counts for 427 workers is very important to gauge.
Phathom Pharmaceuticals Inc (PHAT) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Phathom Pharmaceuticals Inc is 41.98%, while institutional ownership is 50.72%. The most recent insider transaction that took place on Nov 03 ’25, was worth 7,079. In this transaction Principal Accounting Officer of this company sold 524 shares at a rate of $13.51, taking the stock ownership to the 47,407 shares. Before that another transaction happened on Sep 05 ’25, when Company’s Principal Accounting Officer sold 461 for $12.09, making the entire transaction worth $5,573. This insider now owns 47,931 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -1.05 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.08) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.26% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Check out the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). In the past quarter, the stock posted a quick ratio of 2.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.81, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
The latest stats from [Phathom Pharmaceuticals Inc, PHAT] show that its last 5-days average volume of 0.77 million was inferior to 1.55 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 20.67%.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 76.26%, which indicates a significant increase from 4.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.73 in the past 14 days, which was lower than the 0.81 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.64, while its 200-day Moving Average is $9.07. Now, the first resistance to watch is $14.84. This is followed by the second major resistance level at $15.46. The third major resistance level sits at $15.79. If the price goes on to break the first support level at $13.89, it is likely to go to the next support level at $13.56. The third support level lies at $12.94 if the price breaches the second support level.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are currently 71,138K shares outstanding in the company with a market cap of 1.01 billion. Presently, the company’s annual sales total 55,250 K according to its annual income of -334,330 K. Last quarter, the company’s sales amounted to 49,500 K and its income totaled -29,970 K.
